Drug Trial Radar · NCT05877963
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jun 13, 2023
Primary completion
Jan 21, 2027
Study completion Jan 21, 2027
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
Conditions
- Relapsing Multiple Sclerosis
Interventions
UblituximabBiological
Administered as an intravenous (IV) infusion.
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48Time frame: Baseline up to Week 48
- Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of UblituximabTime frame: Predose and at multiple timepoints up to Week 16
Locations
51 sites in 2 countries. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Birmingham, Alabama · Recruiting
TG Therapeutics Investigational Trial Site
Cullman, Alabama · Recruiting
TG Therapeutics Investigational Trial Site
Orange, California · Recruiting
TG Investigational Site
Fort Collins, Colorado · Recruiting
TG Therapeutics Investigational Trial Site
Washington D.C., District of Columbia · Recruiting
TG Therapeutics Investigational Trial Site
Tampa, Florida · Recruiting
TG Therapeutics Investigational Trial Site
Atlanta, Georgia · Recruiting
TG Therapeutics Investigational Trial Site
Atlanta, Georgia · Recruiting
TG Therapeutics Investigational Trial Site
Savannah, Georgia · Recruiting
TG Therapeutics Investigational Trial Site
Chicago, Illinois · Recruiting
TG Therapeutics Investigational Trial Site
Indianapolis, Indiana · Recruiting
TG Therapeutics Investigational Trial Site
Iowa City, Iowa · Recruiting
TG Therapeutics Investigational Trial Site
Overland Park, Kansas · Recruiting
TG Therapeutics Investigational Trial Site
Overland Park, Kansas · Completed
TG Therapeutics Investigational Trial Site
Lutherville, Maryland · Recruiting
TG Therapeutics Investigational Trial Site
Boston, Massachusetts · Recruiting
TG Therapeutics Investigational Trial Site
Boston, Massachusetts · Recruiting
TG Therapeutics Investigational Trial Site
Foxborough, Massachusetts · Recruiting
TG Therapeutics Investigational Trial Site
North Worcester, Massachusetts · Recruiting
TG Therapeutics Investigational Trial Site
Wellesley, Massachusetts · Recruiting
TG Investigational Site
Farmington, Michigan · Recruiting
TG Therapeutics Investigational Trial Site
Golden Valley, Minnesota · Recruiting
TG Therapeutics Investigational Trial Site
Plymouth, Minnesota · Recruiting
TG Therapeutics Investigational Trial Site
St Louis, Missouri · Recruiting
TG Therapeutics Investigational Trial Site
New York, New York · Recruiting
TG Therapeutics Investigational Trial Site
New York, New York · Recruiting
TG Therapeutics Investigational Trial SiteCharlotte
Charlotte, North Carolina · Recruiting
TG Therapeutics Investigational Trial Site
Raleigh, North Carolina · Recruiting
TG Therapeutics Investigational Trial Site
Cincinnati, Ohio · Recruiting
TG Therapeutics Investigational Trial Site
Cleveland, Ohio · Recruiting
TG Therapeutics Investigational Trial Site
Dayton, Ohio · Recruiting
TG Therapeutics Investigational Trial Site
Oklahoma City, Oklahoma · Recruiting
TG Therapeutics Investigational Trial Site
Greenville, South Carolina · Recruiting
TG Therapeutics Investigational Trial Site
Knoxville, Tennessee · Recruiting
TG Therapeutics Investigational Trial Site
Houston, Texas · Completed
TG Therapeutics Investigational Trial Site
Salt Lake City, Utah · Recruiting
TG Therapeutics Investigational Trial Site
Vienna, Virginia · Recruiting
TG Therapeutics Investigational Trial Site
Kirkland, Washington · Recruiting
TG Therapeutics Investigational Trial Site
Seattle, Washington · Recruiting
TG Therapeutics Investigational Trial Site
Spokane, Washington · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.